Abstracts tagged "autoimmune diseases"

Abstract Number: 0776 • ACR Convergence 2024
Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Elliot Akama-Garren¹, Yingying Zhang², Balthasar Heesters³, Padraic Fallon⁴ and Michael Carroll², ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Utrecht University, Utrecht, Netherlands, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells.…
Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Daniel Patton, Alex Chen, Justin Bowser, Kaelen Encarnacion, Jennifer Gardell, Emily Gilbertson, Susan Julien, Meghan Maurer, Brent Meengs, Nadine Morgan, Allison O'Rourke, Cong Tan, Jon Therriault, Kristine Swiderek and Courtney Crane, Mozart Therapeutics, Seattle, WA
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…
Abstract Number: 0956 • ACR Convergence 2024
Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease
Yinlan Wu¹, Yanhong Li² and Yi Liu³, ¹West China Hospital of Sichuan University, Chengdu, Sichuan, China, ²West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ³West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Investigation of Transcriptional Changes in Interstitial Lung Disease (ILD) and Exploration of Functional Effects of Differential Genes and Expressed Proteins in the Development of…
Abstract Number: 1112 • ACR Convergence 2024
Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)
Maximiliano Diaz Menindez¹, Alejandro Diaz Arumir Vergara², Vivian Shing², carolyn mead harvey³, Ana Zamora Martinez² and Vivek Nagaraja⁴, ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Phoenix, ³Mayo Clinic Florida, Jacksonville, FL, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural parenchyma, predominantly affecting the upper lobes.…
Abstract Number: 1325 • ACR Convergence 2024
The Association Between the Number of Teeth and All-Cause as Well as Cardiovascular Mortality Among Patients with RA: NHANES from 1999 to 2004
Jiaqian Zhang¹, Bo Chen², Geng Yin¹ and Qibing Xie³, ¹Department of Rheumatology and Immunology, chengdu, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: Cardiovascular Disease (CVD) is the main cause of death in patients with Rheumatoid Arthritis (RA), and a significant portion of CVD events occur in…
Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Arezou Khosroshahi¹, Sarah Welsh², Liangwei Wang², David Larson² and Nisha Jain², ¹Emory University, Atlanta, GA, ²Amgen, Inc., Rockville, MD
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
Abstract Number: 1664 • ACR Convergence 2024
Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia
ilya Korsunsky¹, Roopa Madhu², Kevin Wei³, Kartik Bhamidipati¹, Miles Tran¹, Sonia Presti¹, Anna Helena Jonsson⁴, Ellen Gravallese⁵, Michael Brenner⁶, Soumya Raychaudhuri¹, Jennifer Seifert⁷, Costantino Pitzalis⁸, Fan Zhang⁹, Larry Moreland¹⁰, V. Michael Holers¹⁰, Michael Clayman¹¹, Myles Lewis¹², Ce Gao¹, Michael J Zuscik¹³ and Accelerating Medicines Partnership Autoimmune and Immune-Mediated Disease¹⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁷University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁸QMUL, Bromley Kent, United Kingdom, ⁹University of Colorado, Aurora, CO, ¹⁰University of Colorado, Denver, CO, ¹¹University of Colorado School of Medicine, Burlington, MA, ¹²Queen Mary University of London, London, United Kingdom, ¹³Department of Orthopedic Surgery, University of Colorado School of Medicine, Aurora, CO, ¹⁴Multiple Institutions, Oklahoma City
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue, resulting in joint damage. In RA, synovia exhibit distinct…
Abstract Number: 1788 • ACR Convergence 2024
Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus
Shady Younis¹, Salvinaz Moutusy², Shaghayegh Jahanbani², Xiaohao Wu², Marlayna Harris², Mahesh Pandit³, Laura van Dam⁴, orr Sharpe⁵, Paul Utz¹ and William Robinson⁶, ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Stanford, ³Stanford University School of Medicine, Stanofrd, ⁴Stanford, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA
Background/Purpose: B cell dysregulation and production of autoantibodies against autoantigens are hallmarks of Systemic lupus erythematosus (SLE). In healthy adults (HC), B cells with autoreactive…
Abstract Number: 1863 • ACR Convergence 2024
Human Endogenous Retroviruses Promote the Aberrant T Cell Differentiation in Systemic Lupus Erythematosus
Xiaoli Min¹, Jiali Wu², Yaqin Yu³, Qianjin Lu⁴ and Ming Zhao⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China (People's Republic), ²Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³Central South University, Changsha, China (People's Republic), ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic)
Background/Purpose: Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and systems. The complex pathogenesis of SLE involved the abnormal activation of CD4+T cells and DNA hypomethylation modification. Human endogenous retroviruses (HERVs)…
Abstract Number: 1996 • ACR Convergence 2024
Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
Elizabeth Wang¹, Genna Braverman², Nilasha Ghosh³, Karmela Kim Chan², Jean-Marie Michot⁴ and Anne Bass⁵, ¹Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Gustave Roussy, Villejuif, France, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) have greatly improved cancer outcomes but they often cause immune-related adverse vents (irAE). "Sarcoid-like" and other granulomatous reactions (GR) are…
Abstract Number: 2208 • ACR Convergence 2024
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Aparna Swaminathan¹, Jeremy Weber², Jamie Todd³, Scott Palmer³, Megan Neely³, Peide Li⁴ and Ann Chauffe⁵, and on behalf of the ILD-PRO Registry investigators, ¹Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT
Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
Abstract Number: 2422 • ACR Convergence 2024
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Anil Bagri¹, Alec Witty¹, Amanda Sims¹, Allan Williams¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Yang Wang¹, Stacey Moreno¹, Allison Aguilar¹, Cara Bickers¹, Yijia Pan¹, Amber Chang¹, Christine Chen¹, Karina Palomares¹, Lauren Fong¹, Nicholas Brookhouser¹, Berhan Mandefro¹, Sajid Mahmood¹, Ramesh Janani¹, Ramzey Abujarour¹, Tom Lee¹, Raedun Clarke¹, Rebecca Elstrom¹, Frank Cichocki², Lilly Wong¹, Betsy Rezner¹, Jode Goodridge¹, Jeffrey Miller² and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Department of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Unprecedented clinical data have recently shown that patients with certain highly refractory autoimmune diseases (AI Dz) treated with conditioning chemotherapy (CCT) and autologous anti-CD19…
Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Joan Merrill¹, Amit Saxena², Martin Aringer³, Yoshiya Tanaka⁴, Xiaofeng Zeng⁵, Peter Wung⁶, Ling Cheng⁶, Thao Doan⁶, Shelly Kafka⁶, David DCruz⁷ and Kristin D'Silva⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ²NYU Grossman School of Medicine, New York, NY, ³University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁶AbbVie Inc., North Chicago, IL, ⁷The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…

« Previous Page
1
…
6
7
8
9
10
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].